| Literature DB >> 35807529 |
Xiaonan Ma1,2, Zihan Liao1,3, Rongxuan Li1,2, Wei Xia4, Honghui Guo4, Jiawei Luo1,3, Huaxin Sheng5, Meihui Tian3,6, Zhipeng Cao1,3.
Abstract
Chronic alcohol exposure can cause myocardial degenerative diseases, manifested as cardiac insufficiency, arrhythmia, etc. These are defined as alcoholic cardiomyopathy (ACM). Alcohol-mediated myocardial injury has previously been studied through metabolomics, and it has been proved to be involved in the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway concerning unsaturated fatty acids biosynthesis and oxidative phosphorylation, which tentatively explored the mechanism of ACM induced by chronic drinking. To further study alcohol-induced myocardial injury, myocardial specimens from a previously successfully established mouse model of ACM were subjected to histological, echocardiographic, and proteomic analyses, and validated by real-time quantitative polymerase chain reaction (qPCR). Results of histopathology and echocardiography showed the hypertrophy of cardiomyocytes, the dilation of ventricles, and decreased cardiac function. Proteomic results, available via ProteomeXchange with identifier PXD032949, revealed 56 differentially expressed proteins (DEPs) were identified, which have the potential to be involved in the KEGG pathway related to fatty acid biosynthesis disorders, lipid metabolism disorders, oxidative stress, and, ultimately, in the development of dilated cardiomyopathy (DCM). The present study further elucidates the underlying effects of myocardial injury due to chronic alcohol intake, laying a foundation for further studies to clarify the potential mechanisms of ACM.Entities:
Keywords: KEGG pathway; alcohol exposure; alcoholic cardiomyopathy; differentially expressed proteins; myocardial injury; proteomics
Mesh:
Substances:
Year: 2022 PMID: 35807529 PMCID: PMC9268295 DOI: 10.3390/molecules27134284
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.927
The results of echocardiography.
| Parameters | Control Group | ACM Group |
|---|---|---|
| LVAW; d (mm) | 0.866 ± 0.069 | 0.599 ± 0.094 # |
| LVAW; s (mm) | 0.772 ± 0.106 | 0.456 ± 0.053 * |
| LVPW; d (mm) | 0.820 ± 0.096 | 0.619 ± 0.098 |
| LVPW; s (mm) | 0.899 ± 0.046 | 0.565 ± 0.110 * |
| LVID; d (mm) | 4.721 ± 0.654 | 6.490 ± 0.587 # |
| LVID; s (mm) | 4.089 ± 0.818 | 5.606 ± 0.788 |
| LV Vol; d (μL) | 79.760 ± 5.867 | 90.470 ± 2.809 # |
| LV Vol; s (μL) | 41.804 ± 3.617 | 57.553 ± 3.571 * |
| EF% | 51.442 ± 2.220 | 38.350 ± 1.925 * |
| FS% | 24.924 ± 1.813 | 19.290 ± 0.848 * |
# p < 0.01; * p <0.05. (EF%: ejection fraction, FS%: fractional shortening, LVPW; d: left ventricular posterior diastolic wall thickness, LVPW; s: left ventricular posterior systolic wall thickness, LVAW; d: left ventricular anterior diastolic wall thickness, LVAW; s: left ventricular anterior systolic wall thickness, LVID; d: left ventricular end-diastolic diameter, LVID;s: left ventricular end-systolic diameter, LV Vol; d: left ventricular end-diastolic volume, and LV Vol; s: left ventricular end-systolic volume).
Figure 1Morphological changes in the myocardium in the control and ACM group. (A) representative H&E staining for the control group (200×); (B) representative H&E staining for the ACM group (200×); (C) representative Sirius Red staining for the control group (200×); (D) representative Sirius Red staining for the ACM group (200×).
Figure 2PCA principal component analysis between the control group and the ACM group.
The up-trend DEPs between the ACM group and the control group.
| Protein | Description | Gene | Fold Change | Trend | |
|---|---|---|---|---|---|
| Q544J2 | Protein-serine/threonine kinase | Pdk4 | 1.436 | 0.002 | up |
| P54869 | Hydroxymethylglutaryl-CoA synthase, mitochondrial | Hmgcs2 | 1.709 | 0.003 | up |
| Q569X3 | U1 small nuclear ribonucleoprotein C | Snrpc | 1.310 | 0.004 | up |
| Q99L15 | Acot1 protein (Fragment) | Acot1 | 1.463 | 0.006 | up |
| Q9QYR9 | Acyl-coenzyme A thioesterase 2, mitochondrial | Acot2 | 1.230 | 0.009 | up |
| P52825 | Carnitine O-palmitoyltransferase 2, mitochondrial | Cpt2 | 1.225 | 0.010 | up |
| Q8R370 | Usher syndrome type-1C protein-binding protein 1 | Ushbp1 | 1.261 | 0.010 | up |
| Q9CQ62 | 2,4-dienoyl-CoA reductase [(3E)-enoyl-CoA-producing], mitochondrial | Decr1 | 1.241 | 0.012 | up |
| Q9DBB5 | Eukaryotic translation initiation factor 4E type 3 | Eif4e3 | 1.208 | 0.016 | up |
| P56501 | Mitochondrial uncoupling protein 3 | Ucp3 | 1.211 | 0.042 | up |
The down-trend DEPs between the ACM group and the control group.
| Protein | Description | Gene | Fold Change | Trend | |
|---|---|---|---|---|---|
| Q4FJX8 | Proteasome subunit beta | Psmb10 | 0.829 | 0.0002 | down |
| A0A087WP87 | RING-type E3 ubiquitin transferase (Fragment) | Rnf2 | 0.824 | 0.001 | down |
| Q61210 | Rho guanine nucleotide exchange factor 1 | Arhgef1 | 0.767 | 0.003 | down |
| A2ADZ4 | Alpha-taxilin (Fragment) | Txlna | 0.813 | 0.004 | down |
| Q3U607 | Uncharacterized protein | Casp8 | 0.820 | 0.005 | down |
| Q91XL1 | Leucine-rich HEV glycoprotein | Lrg1 | 0.732 | 0.006 | down |
| Q684J2 | Serine/threonine kinase 23, muscle-specific serine kinase 1 70 (Fragment) | Srpk3 | 0.825 | 0.006 | down |
| Q3U9M7 | Uncharacterized protein | Lcp1 | 0.827 | 0.008 | down |
| Q4FZE8 | Major urinary protein 1 | Mup22 | 0.779 | 0.009 | down |
| Q8BQ99 | Uncharacterized protein | Mrps2 | 0.795 | 0.011 | down |
| Q4VBD2 | Transmembrane anterior posterior transformation protein 1 | Tapt1 | 0.736 | 0.012 | down |
| P02802 | Metallothionein-1 | Mt1 | 0.723 | 0.014 | down |
| H3BKQ2 | Intraflagellar transport-associated protein (Fragment) | Iftap | 0.817 | 0.016 | down |
| B2RUG7 | Zinc finger RNA binding protein | Zfr | 0.826 | 0.019 | down |
| E9Q559 | Calcium-transporting ATPase | Atp2a3 | 0.764 | 0.020 | down |
| A2AVR6 | Acyl-coenzyme A thioesterase 11 | Acot11 | 0.757 | 0.021 | down |
| A2CEL1 | Major urinary protein 1 | Mup1 | 0.588 | 0.021 | down |
| Q8JZR6 | Electroneutral sodium bicarbonate exchanger 1 | Slc4a8 | 0.799 | 0.022 | down |
| A0A2R2Y2P8 | Tropomyosin 1 kappa | Tpm1 | 0.785 | 0.022 | down |
| P06683 | Complement component C9 | C9 | 0.790 | 0.024 | down |
| Q61696 | Heat shock 70 kDa protein 1A | Hspa1a | 0.764 | 0.025 | down |
| Q4FJR0 | Nudt4 protein | Nudt4 | 0.794 | 0.026 | down |
| Q91XF0 | Pyridoxine-5-phosphate oxidase | Pnpo | 0.818 | 0.026 | down |
| Q6PB44 | Tyrosine-protein phosphatase non-receptor type 23 | Ptpn23 | 0.790 | 0.026 | down |
| Q07456 | Protein AMBP | Ambp | 0.819 | 0.027 | down |
| Q3UIJ3 | Uncharacterized protein | Actc1 | 0.634 | 0.027 | down |
| V9GXQ2 | Predicted gene 17087 | Gm17087 | 0.710 | 0.027 | down |
| Q61753 | D-3-phosphoglycerate dehydrogenase | Phgdh | 0.816 | 0.027 | down |
| O35604 | NPC intracellular cholesterol transporter 1 | Npc1 | 0.824 | 0.029 | down |
| Q8VDP3 | [F-actin]-monooxygenase MICAL1 | Mical1 | 0.832 | 0.032 | down |
| Q3TX70 | t-SNARE coiled-coil homology domain-containing protein | Stx6 | 0.764 | 0.032 | down |
| A0A2R8VHC2 | GTP-binding protein 1 (Fragment) | Gtpbp1 | 0.796 | 0.032 | down |
| H3BK03 | Serum paraoxonase/arylesterase 1 (Fragment) | Pon1 | 0.699 | 0.033 | down |
| Q9QXK3 | Coatomer subunit gamma-2 | Copg2 | 0.821 | 0.034 | down |
| E9Q0U7 | Heat shock protein 105 kDa | Hsph1 | 0.816 | 0.034 | down |
| Q8VE86 | Uncharacterized protein | Lypd8l | 0.821 | 0.037 | down |
| Q5ND36 | Serine or cysteine peptidase inhibitor clade F member 2 | Serpinf2 | 0.701 | 0.037 | down |
| Q3THB4 | L-lactate dehydrogenase | Ldha | 0.822 | 0.038 | down |
| P97379 | Ras GTPase-activating protein-binding protein 2 | G3bp2 | 0.821 | 0.039 | down |
| Q80ZI6 | E3 ubiquitin-protein ligase LRSAM1 | Lrsam1 | 0.803 | 0.040 | down |
| Q9DCV7 | Keratin, type II cytoskeletal 7 | Krt7 | 0.778 | 0.041 | down |
| Q01339 | Beta-2-glycoprotein 1 | Apoh | 0.809 | 0.045 | down |
| E9PW43 | Predicted pseudogene 10320 | Gm10320 | 0.787 | 0.047 | down |
| A1L332 | Phospholipid-transporting ATPase | Atp8a1 | 0.829 | 0.048 | down |
| P29788 | Vitronectin | Vtn | 0.811 | 0.048 | down |
| Q91X72 | Hemopexin | Hpx | 0.786 | 0.048 | down |
Figure 3(A) Volcano plot of the myocardial proteomics data of the control group and the ACM group. DEPs are demonstrated in the volcano map. The abscissa is the logarithm of the protein difference multiple with 2 as the base, and the ordinate is the absolute value of the logarithm of the p value with 10 as the base. Black dots represent proteins that are not significantly different, and red and green represent up-regulated and down-regulated proteins, respectively. (B) Heat map of the differentially expressed metabolites between the control group and the ACM group. The up-regulation and down-regulation proteins among different samples are revealed by cluster analysis. Each row is adjusted for Z value, (observed value-row mean)/row standard deviation. Red and blue represent up-regulation and down-regulation, respectively.
Figure 4(A) Functional enrichment of GO annotation for DEPs. BP: biological process, CC: cellular component, and MF: molecular function. (B) The KEGG pathway enrichment analysis of different groups between the control group and the ACM group. The ratio of the number of differential proteins to the total number of proteins identified is the abscissa. From blue to red dots, it means that the adjusted p value is increasing from large to small, and the degree of enrichment is becoming more and more significant. The size of the dots represents the number of genes enriched in this pathway.
The major KEGG pathways and related DEPs.
| Map Title | Description | |
|---|---|---|
| Biosynthesis of unsaturated fatty acids | 0.006 | Acyl-coenzyme A thioesterase 2, mitochondrial, Acot1 protein (Fragment) |
| Complement and coagulation cascades | 0.009 | Vitronectin, Serine or cysteine peptidase inhibitor clade F member 2, Complement component C9 |
| Fatty acid elongation | 0.011 | Acyl-coenzyme A thioesterase 2, mitochondrial, Acot1 protein (Fragment) |
| Cholesterol metabolism | 0.029 | Beta-2-glycoprotein 1, NPC intracellular cholesterol transporter 1 |
| Legionellosis | 0.029 | Heat shock 70 kDa protein 1A, Uncharacterized protein |
| Vitamin B6 metabolism | 0.035 | Pyridoxine-5-phosphate oxidase |
| Synthesis and degradation of ketone bodies | 0.069 | Hydroxymethylglutaryl-CoA synthase, mitochondrial |
| Toxoplasmosis | 0.079 | Heat shock 70 kDa protein 1A, Uncharacterized protein |
| p53 signaling pathway | 0.080 | Uncharacterized protein |
| Terpenoid backbone biosynthesis | 0.091 | Hydroxymethylglutaryl-CoA synthase, mitochondrial |
| Protein processing in endoplasmic reticulum | 0.094 | Heat shock 70 kDa protein 1A, Heat shock protein 105 kDa, Predicted pseudogene 10320 |
| Apoptosis—multiple species | 0.101 | Uncharacterized protein |
| Dilated cardiomyopathy (DCM) | 0.112 | Uncharacterized protein, Tropomyosin 1 kappa |
| Hypertrophic cardiomyopathy (HCM) | 0.116 | Uncharacterized protein, Tropomyosin 1 kappa |
| Cardiac muscle contraction | 0.120 | Uncharacterized protein, Tropomyosin 1 kappa |
| Mineral absorption | 0.133 | Metallothionein-1 |
| Butanoate metabolism | 0.164 | Hydroxymethylglutaryl-CoA synthase, mitochondrial |
| Protein export | 0.164 | Predicted pseudogene 10320 |
| Adrenergic signaling in cardiomyocytes | 0.169 | Uncharacterized protein, Tropomyosin 1 kappa |
| SNARE interactions in vesicular transport | 0.183 | t-SNARE coiled-coil homology domain-containing protein |
Figure 5PPI network of DEPs between control group and ACM group.
Figure 6Real-time qPCR results of Acot 1, Mup 1, Mt 1, TPM 1, and Actc 1 mRNA (# p < 0.01; * p < 0.05).